Catalent’s Development & Clinical Services business provides clinical supply services, analytical chemistry, respiratory product development, regulatory consulting, and biologics cell line development.
Aptuit chairman and CEO Timothy Tyson said focusing on their expertise in discovery and development services leverages their position, and allows them to concentrate on delivering scientific services from discovery to mid-phase development.
The closing of the transaction is subject to customary closing conditions including approval from regulatory authorities, and is expected to occur by the end of the calendar year.
The other terms of the deal were not been disclosed.